Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan

Yi Chun Lin, Yu Tsung Huang, Pei Jane Tsai, Tai Fen Lee, Nan Yao Lee, Chun Hsing Liao, Shyr Yi Lin, Wen Chien Ko, Po Ren Hsueh

研究成果: 雜誌貢獻文章

37 引文 (Scopus)

摘要

The antimicrobial susceptibility and virulence factors of Clostridium difficile clinical isolates in Taiwan have not previously been reported. One hundred and thirteen isolates were collected from two major teaching hospitals in Taiwan from 2001 to 2009. Molecular typing was performed by an automated repetitive extragenic palindromic sequence-based PCR (rep-PCR) method (DiversiLab; Bacterial Barcodes, Inc., Athens, GA) and PCR ribotyping. Detection of tcdA, tcdB, cdtA, and cdtB genes was performed using a multiplex PCR assay, and gyrA and gyrB genes of moxifloxacin-nonsusceptible isolates were sequenced. All isolates were susceptible to vancomycin and metronidazole. Ninety-five (84%) isolates were susceptible to moxifloxacin, and the MIC90 for nemonoxacin was 4 μg/ml. Tigecycline showed favorable antibacterial activity (MIC90 of 0.06 μg/ml). Thirteen rep-PCR types were identified as a predominant rep-PCR type (type A; non-North American pulsed-field gel electrophoresis type 1 [NAP1], -NAP7, or -NAP8) accounting for 52.2% (59 isolates). Nine of 18 moxifloxacinnonsusceptible isolates belonged to the rep-PCR type A. The rep-PCR type A and C isolates were distinct from NAP1 (ribotype 027) and NAP8 (ribotype 078) as determined by PCR ribotyping. Seventy-four (65%) isolates harbored tcdA and tcdB, and 15 (13%) harbored cdtAB encoding binary toxin. Eleven isolates had a gene deletion in tcdC, including a 39-bp deletion (9 isolates) and an 18-bp deletion (2). In conclusion, dissemination of a predominant C. difficile clone in southern and northern Taiwan was noted. However, no NAP1 (ribotype 027) isolate could be discovered in this study.

原文英語
頁(從 - 到)1701-1705
頁數5
期刊Antimicrobial Agents and Chemotherapy
55
發行號4
DOIs
出版狀態已發佈 - 四月 2011

指紋

Molecular Epidemiology
Clostridium difficile
Taiwan
Ribotyping
Polymerase Chain Reaction
Molecular Typing
Pulsed Field Gel Electrophoresis
Multiplex Polymerase Chain Reaction
Metronidazole
Gene Deletion
Virulence Factors
Vancomycin
Teaching Hospitals
Genes
Clone Cells

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

引用此文

Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan. / Lin, Yi Chun; Huang, Yu Tsung; Tsai, Pei Jane; Lee, Tai Fen; Lee, Nan Yao; Liao, Chun Hsing; Lin, Shyr Yi; Ko, Wen Chien; Hsueh, Po Ren.

於: Antimicrobial Agents and Chemotherapy, 卷 55, 編號 4, 04.2011, p. 1701-1705.

研究成果: 雜誌貢獻文章

Lin, Yi Chun ; Huang, Yu Tsung ; Tsai, Pei Jane ; Lee, Tai Fen ; Lee, Nan Yao ; Liao, Chun Hsing ; Lin, Shyr Yi ; Ko, Wen Chien ; Hsueh, Po Ren. / Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan. 於: Antimicrobial Agents and Chemotherapy. 2011 ; 卷 55, 編號 4. 頁 1701-1705.
@article{ec6494f1585c40708b2a24162a4fcf97,
title = "Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan",
abstract = "The antimicrobial susceptibility and virulence factors of Clostridium difficile clinical isolates in Taiwan have not previously been reported. One hundred and thirteen isolates were collected from two major teaching hospitals in Taiwan from 2001 to 2009. Molecular typing was performed by an automated repetitive extragenic palindromic sequence-based PCR (rep-PCR) method (DiversiLab; Bacterial Barcodes, Inc., Athens, GA) and PCR ribotyping. Detection of tcdA, tcdB, cdtA, and cdtB genes was performed using a multiplex PCR assay, and gyrA and gyrB genes of moxifloxacin-nonsusceptible isolates were sequenced. All isolates were susceptible to vancomycin and metronidazole. Ninety-five (84{\%}) isolates were susceptible to moxifloxacin, and the MIC90 for nemonoxacin was 4 μg/ml. Tigecycline showed favorable antibacterial activity (MIC90 of 0.06 μg/ml). Thirteen rep-PCR types were identified as a predominant rep-PCR type (type A; non-North American pulsed-field gel electrophoresis type 1 [NAP1], -NAP7, or -NAP8) accounting for 52.2{\%} (59 isolates). Nine of 18 moxifloxacinnonsusceptible isolates belonged to the rep-PCR type A. The rep-PCR type A and C isolates were distinct from NAP1 (ribotype 027) and NAP8 (ribotype 078) as determined by PCR ribotyping. Seventy-four (65{\%}) isolates harbored tcdA and tcdB, and 15 (13{\%}) harbored cdtAB encoding binary toxin. Eleven isolates had a gene deletion in tcdC, including a 39-bp deletion (9 isolates) and an 18-bp deletion (2). In conclusion, dissemination of a predominant C. difficile clone in southern and northern Taiwan was noted. However, no NAP1 (ribotype 027) isolate could be discovered in this study.",
author = "Lin, {Yi Chun} and Huang, {Yu Tsung} and Tsai, {Pei Jane} and Lee, {Tai Fen} and Lee, {Nan Yao} and Liao, {Chun Hsing} and Lin, {Shyr Yi} and Ko, {Wen Chien} and Hsueh, {Po Ren}",
year = "2011",
month = "4",
doi = "10.1128/AAC.01440-10",
language = "English",
volume = "55",
pages = "1701--1705",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan

AU - Lin, Yi Chun

AU - Huang, Yu Tsung

AU - Tsai, Pei Jane

AU - Lee, Tai Fen

AU - Lee, Nan Yao

AU - Liao, Chun Hsing

AU - Lin, Shyr Yi

AU - Ko, Wen Chien

AU - Hsueh, Po Ren

PY - 2011/4

Y1 - 2011/4

N2 - The antimicrobial susceptibility and virulence factors of Clostridium difficile clinical isolates in Taiwan have not previously been reported. One hundred and thirteen isolates were collected from two major teaching hospitals in Taiwan from 2001 to 2009. Molecular typing was performed by an automated repetitive extragenic palindromic sequence-based PCR (rep-PCR) method (DiversiLab; Bacterial Barcodes, Inc., Athens, GA) and PCR ribotyping. Detection of tcdA, tcdB, cdtA, and cdtB genes was performed using a multiplex PCR assay, and gyrA and gyrB genes of moxifloxacin-nonsusceptible isolates were sequenced. All isolates were susceptible to vancomycin and metronidazole. Ninety-five (84%) isolates were susceptible to moxifloxacin, and the MIC90 for nemonoxacin was 4 μg/ml. Tigecycline showed favorable antibacterial activity (MIC90 of 0.06 μg/ml). Thirteen rep-PCR types were identified as a predominant rep-PCR type (type A; non-North American pulsed-field gel electrophoresis type 1 [NAP1], -NAP7, or -NAP8) accounting for 52.2% (59 isolates). Nine of 18 moxifloxacinnonsusceptible isolates belonged to the rep-PCR type A. The rep-PCR type A and C isolates were distinct from NAP1 (ribotype 027) and NAP8 (ribotype 078) as determined by PCR ribotyping. Seventy-four (65%) isolates harbored tcdA and tcdB, and 15 (13%) harbored cdtAB encoding binary toxin. Eleven isolates had a gene deletion in tcdC, including a 39-bp deletion (9 isolates) and an 18-bp deletion (2). In conclusion, dissemination of a predominant C. difficile clone in southern and northern Taiwan was noted. However, no NAP1 (ribotype 027) isolate could be discovered in this study.

AB - The antimicrobial susceptibility and virulence factors of Clostridium difficile clinical isolates in Taiwan have not previously been reported. One hundred and thirteen isolates were collected from two major teaching hospitals in Taiwan from 2001 to 2009. Molecular typing was performed by an automated repetitive extragenic palindromic sequence-based PCR (rep-PCR) method (DiversiLab; Bacterial Barcodes, Inc., Athens, GA) and PCR ribotyping. Detection of tcdA, tcdB, cdtA, and cdtB genes was performed using a multiplex PCR assay, and gyrA and gyrB genes of moxifloxacin-nonsusceptible isolates were sequenced. All isolates were susceptible to vancomycin and metronidazole. Ninety-five (84%) isolates were susceptible to moxifloxacin, and the MIC90 for nemonoxacin was 4 μg/ml. Tigecycline showed favorable antibacterial activity (MIC90 of 0.06 μg/ml). Thirteen rep-PCR types were identified as a predominant rep-PCR type (type A; non-North American pulsed-field gel electrophoresis type 1 [NAP1], -NAP7, or -NAP8) accounting for 52.2% (59 isolates). Nine of 18 moxifloxacinnonsusceptible isolates belonged to the rep-PCR type A. The rep-PCR type A and C isolates were distinct from NAP1 (ribotype 027) and NAP8 (ribotype 078) as determined by PCR ribotyping. Seventy-four (65%) isolates harbored tcdA and tcdB, and 15 (13%) harbored cdtAB encoding binary toxin. Eleven isolates had a gene deletion in tcdC, including a 39-bp deletion (9 isolates) and an 18-bp deletion (2). In conclusion, dissemination of a predominant C. difficile clone in southern and northern Taiwan was noted. However, no NAP1 (ribotype 027) isolate could be discovered in this study.

UR - http://www.scopus.com/inward/record.url?scp=79953203949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953203949&partnerID=8YFLogxK

U2 - 10.1128/AAC.01440-10

DO - 10.1128/AAC.01440-10

M3 - Article

VL - 55

SP - 1701

EP - 1705

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -